Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04922723
Title Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma (PRIDE)
Acronym PRIDE
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors West Virginia University
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.